John Hamm

7.6k total citations · 3 hit papers
74 papers, 5.2k citations indexed

About

John Hamm is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John Hamm has authored 74 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in John Hamm's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (9 papers). John Hamm is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Research Studies (13 papers) and Cancer therapeutics and mechanisms (9 papers). John Hamm collaborates with scholars based in United States, Canada and United Kingdom. John Hamm's co-authors include J. Randolph Hecht, Steven Gallinger, Daniel de Castro, H. Au, Malcolm J. Moore, Wendy R. Parulekar, Keyue Ding, Arié Figer, P. Murawa and David Walde and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

John Hamm

72 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2007 2.9k citations John Hamm, J. Randolph Hecht et al. Journal of Clinical Oncology profile →
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

2005 709 citations Fairooz F. Kabbinavar, Joseph J. Schulz et al. Journal of Clinical Oncology profile →
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

2022 104 citations Christina Tsien, Stephanie L. Pugh et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by John Hamm

Since Specialization

Citations

This map shows the geographic impact of John Hamm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hamm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hamm more than expected).

Fields of papers citing papers by John Hamm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hamm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hamm. The network helps show where John Hamm may publish in the future.

Co-authorship network of co-authors of John Hamm

This figure shows the co-authorship network connecting the top 25 collaborators of John Hamm. A scholar is included among the top collaborators of John Hamm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hamm. John Hamm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) 2024 ·Annals of Oncology ·(unknown), Martin Reck, Enriqueta Felip, (unknown), (unknown), Rüediger Liersch, Satoshi Oizumi, Hiroshi Tanaka, John Hamm, Steve McCune, (unknown), (unknown), (unknown), Silvia Novello, (unknown), (unknown), (unknown), (unknown), C.Z. Zhou	5
2	Strengthening vaccination assessment at a southern oncology center: A quality improvement endeavor. 2024 ·JCO Oncology Practice ·John Hamm, Laura S. Guy	0
3	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors 2023 ·SHILAP Revista de lepidopterología ·Jong Chul Park, David Berz, Manish Sharma, Erminia Massarelli, Ralph J. Hauke, Frank Tsai, David S. Hong, (unknown), Justin Call, Jennifer W. Carlisle, Rachel E. Sanborn, Naomi B. Haas, John Hamm, D. Ross Camidge, Alexander I. Spira, (unknown), (unknown), (unknown), Anthony W. Tolcher	2
4	735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer 2023 ·SHILAP Revista de lepidopterología ·Jamie Moon, (unknown), (unknown), (unknown), John Hamm, Benedito A. Carneiro, Trisha M. Wise‐Draper, Breelyn A. Wilky, Rachel E. Sanborn, Anthony B. El-Khoueiry, Marco A. Purbhoo, Dave S.�B. Hoon, Marc Van Dijk	3
5	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) 2022 ·Breast Cancer Research and Treatment ·Charles E. Geyer, Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J. Ward, Jonathan Polikoff, Adam Brufsky, Louise Provencher, Alexander Paterson, John Hamm, (unknown), Luis Báez-Díaz, Thomas B. Julian, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	4
6	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma breakdown → 2022 ·Journal of Clinical Oncology ·Christina Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, M.M. Matuszak, Enrico C. Lallana, Jiayi Huang, Özer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John Hamm, Kevin Oh, Arif N. Ali, Michelle M. Kim, Scott Lindhorst, Minesh P. Mehta	104
7	488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC) 2022 ·Annals of Oncology ·Michael T. Schweizer, (unknown), (unknown), Atish D. Choudhury, Vadim Doronin, Raid Aljumaily, (unknown), Richard C. Frank, John Hamm, Víctor Moreno, Vladimir Vorobyev, (unknown), (unknown), (unknown), Tsung H. Lin, (unknown), (unknown), (unknown), Melissa L. Johnson	4
8	2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC 2021 ·Annals of Oncology ·C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, (unknown), M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello	41
9	Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553) 2017 ·Investigational New Drugs ·Susanne M. Arnold, Kari Chansky, Markos Leggas, Michael A. Thompson, John L. Villano, John Hamm, Rachel E. Sanborn, Glen J. Weiss, Gurkamal Chatta, Maria Q. Baggstrom	11
10	Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study 2013 ·Annals of Oncology ·Brian L. Samuels, Sant P. Chawla, Shreyaskumar Patel, Margaret von Mehren, John Hamm, (unknown), Scott M. Schuetze, (unknown), (unknown), George D. Demetri	104
11	Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study 2013 ·The Lancet Oncology ·Ahmad Awada, Agustin A. García, Stephen L. Chan, Guy Jérusalem, Robert E. Coleman, Manon Huizing, (unknown), (unknown), John Hamm, Peter Barrett‐Lee, Véronique Cocquyt, Kostandinos Sideras, David Young, Carol Zhao, Yen Lin Chia, Ute Hoch, Alison L. Hannah, Edith A. Perez	49
12	Testing the Diagnostic Value of Electrical Ear Canal Stimulation in Cochlear Implant Candidates by Functional Magnetic Resonance Imaging 2008 ·Audiology and Neurotology ·Katrin Neumann, Christine Preibisch, Joachim Spreer, Peter Raab, John Hamm, Harald Α. Euler, Heinrich Lanfermann, Silke Helbig, Jan Kiefer	2
13	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer 2006 ·Journal of Thoracic Oncology ·Alberto Chiappori, Peter Ellis, John Hamm, Jacob D. Bitran, Irene Eiseman, (unknown), (unknown), Stephen C. Olson, Peter F. Lenehan, Ralph Zinner	12
14	Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial breakdown → 2005 ·Journal of Clinical Oncology ·Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod, Taral Patel, John Hamm, J. Randolph Hecht, R. Mass, (unknown), B. Nelson, William Novotny	709
15	The Efficacy of Recombinant Human Granulocyte Colony-Stimulating Factor and Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor in Permitting the Administration of Higher Doses of Cyclophosphamide in a Doxorubicin-Cyclophosphamide Combination 1994 ·American Journal of Clinical Oncology ·Eleftherios P. Mamounas, Sarah Anderson, D. Lawrence Wickerham, Robert A. Clark, Ronald G. Stoller, John Hamm, Jane A. Stewart, Harry D. Bear, Andrew G. Glass, Rafael Bornstein, (unknown)	13
16	Inefficacy of Low-Dose Continuous Oral Etoposide in Non-Small Cell Lung Cancer 1994 ·American Journal of Clinical Oncology ·Martin S. Blumenreich, (unknown), Carole B. Miller, (unknown), (unknown), (unknown), John Hamm, Janell Seeger, Lee Robinson, Phillip L. Hagan, Daniel Sullivan, Thomas Woodcock	8
17	Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. 1994 ·Journal of Clinical Oncology ·John Hamm, Joan H. Schiller, (unknown), M. M. Oken, Richard I. Fisher, Frances A. Shepherd, (unknown)	40
18	High-Dose Chlorambucil and Dexamethasone for Relapsed Non-Hodgkinʼs Lymphomas 1993 ·American Journal of Clinical Oncology ·Geetha Joseph, Terence J. Hadley, Benjamin Djulbegović, John Hamm, Janell Seeger, Martin S. Blumenreich, Thomas Woodcock	4
19	Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer 1990 ·Breast Cancer Research and Treatment ·Peter Köhler, John Hamm, Valerie J. Wiebe, Michael W. DeGregorio, Irving Shemano, Douglass C. Tormey	21
20	A Phase I Trial of Toremifene, a New Antiestrogen 1990 ·Cancer Investigation ·John Hamm	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact